Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

5.520 +0.180 (+3.37%)
Streaming Delayed Price Updated: 10:22 AM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Gapping stocks in Wednesday's session ↗
Via Chartmill
News headline image
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to present at upcoming investor conferences in September
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
From Alvotech
Via GlobeNewswire
Alvotech (NASDAQ:ALVO) Q1 2026 Results Miss Estimates, Shares Drop Over 9% as Revenue and EPS Fall Short ↗
Via Chartmill
News headline image
Alvotech Q2 Earnings Call Highlights ↗
Alvotech (NASDAQ:ALVO) said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed... 
Via MarketBeat
Topics Earnings
News headline image
Alvotech Q2 2026 Earnings Call Transcript ↗
Alvotech (NASDAQ:ALVO) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga... 
Via Benzinga
Topics Earnings
News headline image
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Report Financial Results for H1 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech announces successful closure of FDA inspection of manufacturing facility
From Alvotech
Via GlobeNewswire
News headline image
Alvotech further strengthens liquidity by securing term loan facility of $75 million
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
From Alvotech
Via GlobeNewswire
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
From Alvotech
Via GlobeNewswire
News headline image
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock? ↗
Driving revenue growth and earnings growth are two different things. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions ↗
Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilars-focused company is entering a “critical inflection period” as it advances several limited-competition products through... 
Via MarketBeat
News headline image
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End ↗
Alvotech (NASDAQ:ALVO) is at an “inflection point” after more than a decade of investment in its biosimilar platform, Founder and Executive Chairman Róbert Wessman said at the Jefferies Global... 
Via MarketBeat
News headline image
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
From Alvotech
Via GlobeNewswire
News headline image
Main Results of 2026 Annual and Extraordinary General Meeting
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to present at upcoming investor conferences in June
From Alvotech
Via GlobeNewswire
News headline image
Alvotech (ALVO) Q4 2025 Earnings Transcript ↗
Alvotech (ALVO) Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Bonds
News headline image
Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End ↗
Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilar developer is preparing to resubmit three biologics license applications to the U.S. Food and Drug Administration in June... 
Via MarketBeat
News headline image
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
From Alvotech
Via GlobeNewswire
News headline image
Alvotech (ALVO) Q1 2026 Earnings Transcript ↗
Alvotech (ALVO) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Alvotech Q1 2026 Financial Results
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces a Change in its Executive Team
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Report Financial Results for the First Quarter of 2026
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.